Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The work coming out of the KU Leuven Sports Analytics Lab is genuinely useful and clubs apply it for a range of purposes

    60% confidence
  • Manual soccer game annotation is a nightmare for data analysts, taking up to six hours per game

    60% confidence
  • Jesse Davis's lab is the most influential sports analytics lab in soccer

    60% confidence
  • Over the last five to ten years, the number of long shots in soccer has dramatically increased as a result of data showing their value

    60% confidence
  • When the ball is in the middle third of the pitch, kicking it out of bounds on the opponent's side can put the kicking team within 10 actions of a goal

    60% confidence
  • Chelsea could gain 1.6 more goals per season by shooting from distance 20% more often

    60% confidence
  • Jan Van Haaren and the KU Leuven lab laid the intellectual foundations of how soccer is analyzed today

    60% confidence
  • Davis is motivated to solve problems that arise in real settings and see his work have an impact

    60% confidence
  • Club Brugge's collaboration with the KU Leuven lab is centered on translating the team's football philosophy into measurable, data-driven outputs

    60% confidence
  • The vast majority of soccer actions don't lead to a goal or even a shot, making it hard to derive a winning strategy from data

    60% confidence
  • Many people in industry use the KU Leuven Sports Analytics Lab's open-source code in their daily workflows

    60% confidence
  • Significant progress has been made on transformer-based automated soccer annotation, but the problem remains quite hard

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Source | Via News | Via News